All In Biotech

Drug Trial Radar · NCT05092347

A Study to Learn How Safe and Tolerable Vonsetamig is in Adult Patients With Chronic Kidney Disease (CKD) Who Need Kidney Transplantation and Are Highly Sensitized to Human Leukocyte Antigen (HLA)

A Dose Escalation and Proof-of-Concept Study of Vonsetamig (BCMA × CD3 Bispecific Antibody) for Desensitization of Chronic Kidney Disease Patients in Need of Kidney Transplantation Who Are Highly Sensitized to Human Leukocyte Antigen

Last checked: Nov 19, 2026Latest source record: Jun 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

43

Actual

Start

Aug 2, 2022

Primary completion

Nov 22, 2027

Study completion Nov 22, 2027

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Oct 25, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether vonsetamig will safely decrease anti-HLA antibodies to allow for kidney transplantation. Vonsetamig is being studied for treatment of patients in need of kidney transplantation who are highly sensitized to HLA. The study is looking at several other research questions, including: * Side effects that may be experienced from taking vonsetamig * How vonsetamig works in the body * How much vonsetamig is present in the blood * If vonsetamig works to lower levels of antibodies to HLA

Conditions

  • Chronic Kidney Disease (CKD)

Interventions

  • VonsetamigDrug

    Administered by intravenous (IV) infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse event(s) of interest (AEI) from the first dose through end of the safety observation periodTime frame: Up to approximately 6 weeks
  2. Incidence and severity of treatment-emergent adverse events (TEAE)s from the first study drug dose up to the end of the studyTime frame: Up to 78 weeks

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Cedars-Sinai Medical Center

    Los Angeles, California

  • University of California Irvine

    Orange, California

  • Connie Frank Transplant Center at UCSF

    San Francisco, California

  • Yale University of Medicine

    New Haven, Connecticut

  • Medstar Georgetown Transplant Institute - 2-PHC

    Washington D.C., District of Columbia

  • Comprehensive Transplant Center

    Chicago, Illinois

  • John Hopkins Hospital

    Baltimore, Maryland

  • University of Minnesota

    Minneapolis, Minnesota

  • New York University Langone Health

    New York, New York

  • Penn Transplant Institute

    Philadelphia, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.